[1] Gourlay ML, Fine JP, Preisser JS, et al. Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012; 366(3):225-233.[2] Omura Y, Nishio Y, Kashiwagi A. Osteoporosis and atherosclerosis. Clin Calcium. 2007;17(3):346-353.[3] Sennerby U, Melhus H, Gedeborg R et al. Cardiovascular diseases and risk of hip fracture. JAMA. 2009;302(15):1666-1673.[4] Danilevicius CF, Lopes JB, Pereira RM. Bone metabolism and vascular Calcification. Braz J Med Biol Res. 2007;40(4): 435-442.[5] Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004; 89(9):4246-4253.[6] Marcovitz PA, Tran HH, Franklin BA, et al. Usefulness of bone min¬eral density to predict significant coronary artery disease. Am J Cardiol. 2005;96(8):1059-1063. [7] Farhat GN, Strotmeyer ES, Newman AB, et al. Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health aging and body composition study. Calcif Tissue Int. 2006; 79(2): 102-111.[8] Tanko LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int. 2003;73(1):15-20.[9] Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008; 51(6):627-633.[10] Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States. Arch Intern Med. 2007;167(11):1159-1165.[11] Tintut Y, Morony S, Demer LL. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vasc Biol. 2004;24(2):6-10.[12] De Simone G, Gottdiener JS, Chinali M, et al. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J. 2008; 29(6):741-747.[13] de Simone G, Verdecchia P, Pede S, et al. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension. 2002;40(4):470-476.[14] Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol. 2008;102(9):1131-1135.[15] Grundberg E, Brandstrom H, Ribom EL, et al. Genetic variation in the human vitamin D receptor is associated with muscle strength, fat mass and body weight in Swedish women. Eur J Endocrinol. 2004;150(3):323-328.[16] Pedram A, Razandi M, Lubahn D, et al. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology. 2008;149(7):3361-3369.[17] Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Weiting Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12): 1440-1463.[18] Bakkaloglu SA, Saygili A, Sever L, et al. Assessment of cardiovascular risk in paediatric peritoneal dialysis patients: a Turkish Pediatric Peritoneal Dialysis Study Group (TUPEPD) report. Nephrol Dial Transplant. 2009;24(11):3525-3532.[19] Zhu WH, Li ZC, Zhang ZY, et al. Linchuang Xinxueguanbing Zazhi. 2011;27(08):583-585. 朱卫华,李自成,张再勇,等.绝经后女性高血压伴糖耐量减低患者骨密度分析[J].临床心血管病杂志,2011,27(08):583-585.[20] He L, Huang L. Beijing Zhongyiyao Daxue Xuebao(Zhongyi Linchuang Ban). 2008;15(02):1-3. 贺琳,黄力.高血压病与原发性骨质疏松症的相关性研究[J].北京中医药大学学报(中医临床版),2008,15(02):1-3.[21] Xiang H, Li YQ, Yuan H, et al. Zhongguo Guzhi Shusong Zazhi. 2011;17(07):570-573. 向红,李玉琴,袁宏,等.原发性高血压患者骨质疏松与25羟维生素D代谢的关系[J].中国骨质疏松杂志,2011,17(07):570-573.[22] Chen K, Lai YL, Xue L, et al. Zhongguo Guzhi Shusong Zazhi. 2009;15(09):661-663. 陈可,赖玉链,薛莲,等.高血压病对绝经后妇女骨密度的影响[J].中国骨质疏松杂志,2009,15(09):661-663.[23] Zhang XZ, Wang B, Xuan M, et al. Dier Junyi Daxue Xuebao. 2009;30(04):424-427. 张秀珍,王博,宣淼,等.老年女性2型糖尿病患者高血压与骨质疏松的关系[J].第二军医大学学报,2009,30(04): 424-427.[24] He Z. Zhongguo Wuzhenxue Zazhi. 2008;8(25):6092-6093. 何真.老年原发性高血压骨密度变化分析[J].中国误诊学杂志, 2008,8(25):6092-6093.[25] Chen YQ, Wei FC, Liu DY. Jianyan Yixue yu Linchuang. 2011; 8(5):521-523. 陈玉群,魏富春,刘丹妍.骨质疏松与代谢紊乱的相关性分析[J].检验医学与临床,2011,8(5):521-523.[26] Lin QM, Chen F. Zhonghua Gaoxueya Zazhi. 2011;19(07): 683-685. 林庆明,陈锋.老年男性高血压患者的骨密度[J].中华高血压杂志, 2011,19(07):683-685.[27] Zhang ZY, Li ZC. Yixue Zongshu. 2011;17(03):327-330. 张在勇,李自成.高血压与骨质疏松发病机制中细胞因子的变化[J].医学综述,2011,17(03):327-330.[28] Zhu WH, Li ZC, Zhang ZY, et al. Lingnan Xinxueguanbing Zazhi. 2011;S1. 朱卫华,李自成,张再勇,等.绝经后女性高血压病伴糖耐量减低患者骨密度分析[J].岭南心血管病杂志,2011,S1.[29] Li J, Yang XL, Guo JA, et al. Zhongguo Shiyong Neike Zazhi. 2010;S1. 李洁,杨希立,郭晋爱,等.老年冠心病与骨质疏松的相关性研究[J].中国实用内科杂志, 2010,S1.[30] Wang SG, Zheng HX, Yuan F, et al. Quanke Yixue Linchuang yu Jiaoyu. 2009;7(06):579-581. 王绍冠,郑和昕,袁放,等.老年男性2型糖尿病患者骨密度与冠心病的相关性[J].全科医学临床与教育,2009,7(06): 579-581.[31] Wang L. Zhongguo Shiyong Yiyao. 2010;5(11):40-42. 王黎.绝经后女性2型糖尿病患者骨密度与冠心病的相关性[J].中国实用医药,2010,5(11):40-42.[32] Xue YH, Xie QC, Xu X, et al. Zhongguo Guzhi Shusong Zazhi. 2008;14(06):388-390,395. 薛月华,谢匡成,许翔,等.绝经期冠心病妇女血脂水平与骨密度的研究[J].中国骨质疏松杂志,2008,14(06):388-390,395.[33] Deng CM, Qian XM, Liu Q. Zhonghua Quanke Yixue. 2009; 7(04):427-428. 邓超明,钱雪梅,刘琦.高龄冠心病并存骨质疏松患者的舒适护理[J].中华全科医学,2009,7(04):427-428.[34] Xie LN, Zhong XY, Wang LJ, et al. Linchuang Xinxueguanbing Zazhi. 2008;24(02):103-105. 谢莲娜,钟雪焱,王丽君,等.阿托伐他汀对老年冠心病患者骨密度的影响[J].临床心血管病杂志,2008,24(02):103-105.[35] Zhao Y, Xing Y, Liu WY, et al. Zhongguo Guzhi Shusong Zazhi. 2011;17(12):1068-1072. 赵圆,邢艳,刘文亚,等.基于定量CT对绝经后无症状冠心病患者腰椎骨密度与冠脉钙化的相关研究[J].中国骨质疏松杂志,2011, 17(12):1068-1072.[36] Ji Y, Wang J. Zhongguo Laonianxue Zazhi. 2007;27(20): 2038-2039. 季勇,王珺.冠心病患者骨质疏松与动脉硬化的关系[J].中国老年学杂志,2007,27(20):2038-2039.[37] Dou QH, Zhu MS. Zhongguo Guzhi Shusong Zazhi. 2011; 17(09): 770-772. 窦清惠,朱梅生.147例维吾尔族和汉族男性冠心病患者骨量结果分析[J].中国骨质疏松杂志,2011,17(09):770-772.[38] Zhao Q, Yang J, Zhang LC, et al. Xiandai Shengwu Yixue Jinzhan. 2011;S2. 赵勤,杨进,张林潮,等.绝经后女性心血管危险因素与骨密度的相关关系[J]. 现代生物医学进展, 2011,S2.[39] Wenger N. The female heart is vulnerable to cardiovascular disease: emerging prevention evidence for women must inform emerging prevention strategies for women. Circ Cardiovasc Qual Outcomes. 2010;3(2):118-119.[40] Vos HM, van Kuik A, Janse ME, et al. Prevention of coronary heart disease and osteoporosis in women aged 45 to 49 years: a challenging role for general practitioners. Menopause. 2010;17(2):290-294.[41] Bayauli MP, Lepira FB, Kayembe PK, et al. Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echocardiographic study. Cardiovasc J Afr. 2012;23(2):73-77.[42] Makoto O, Yukiko Y, Hiroyuki T, et al. Home systolic blood pressure on the morning of dialysis days has prognostic impact for hypertensive hemodialysis patients. Clin Exp Nephrol. 2012;16(3):427-432.[43] Guerra F, Mancinelli L, Buglioni A, et al. Microalbuminuria and left ventricular mass in overweight and obese hypertensive patients: role of the metabolic syndrome. High Blood Press Cardiovasc Prev. 2011;18(4):195-201.[44] Mahmoud S, Ayman AH, Ghada I, et al. Relation between postmenopausal osteoporosis and coronary and peripheral arterial disease. Middle East Fertility Society J. 2012; 1-6. (in press).[45] Young HL, Jinho Shin, Jae UL, et al. Bone mineral density is an independent determinant of left ventricular mass index in the general female population. Korean Circ J. 2010;40(11): 573-580.[46] Ihsane H, Fadoua A, Hamza K, et al. Low bone mineral density is related to atherosclerosis in postmenopausal Moroccan women. BMC Public Health. 2009;9:388-396.[47] Sinnott B, Syed I, Sevrukov A, et al. Coronary calcification and osteoporosis in men and postmeno -pausal women are independent processes associated with aging. Calcif Tissue Int. 2006;78(4):195-202.[48] Kiel DP, Kauppila LI, Cupples LA, et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int. 2001; 68(5):271-276.[49] Liliana CB, Wanda HS, Bartosz B, et al. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. Kardiol Pol. 2011;69(6): 573-578.[50] Salles GF, Fiszman R, Cardoso CR,et al. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50(4):723-728.[51] Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States. Arch Intern Med. 2007;167(11):1159-1165.[52] Fiore CE, Pennisi P, Pulvirenti I, et al. Bisphosphonates and atherosclerosis. J Endocrinol Invest. 2009;32(4 Suppl):38-43. |